ArticleNature reviews. Endocrinology2025
Balancing weight and muscle loss in GLP1 receptor agonist therapy.
Article in Nature reviews. Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Association of hypertension and diabetes with opioid initiation and progression to long-term use after osteoarthritis diagnosis: A population-based register cohort study in Sweden.Osteoarthritis and cartilage open · 2026Article
- Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/mDiabetes, obesity & metabolism · 2026Article
- Systemic Metabolic and Skeletal Muscle-Related Profiles Associated with Annual Axial Elongation Across Optical Myopia-Control Strategies in Adolescents: A Retrospective Cohort Study.Ophthalmology and therapy · 2026Article
- Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia · 2026Article
- Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.Cell reports. Medicine · 2026Review
- Mitochondrial Proteostasis Links Diabetes and Sarcopenia: Cross-Scale Convergence from Experimental Models to Human Multi-Omics.Diabetes & metabolism journal · 2026Review
- The need for clinical studies assessing whether weight loss improves functional outcome after stroke in diabetes.BMC medicine · 2026Review
- Adipose-muscle crosstalk during the menopausal transition: mechanistic links to sarcopenic obesity in midlife women.Frontiers in endocrinology · 2026Review
- How and why does aging occur? Updating evolutionary theory to meet a new era of data.Evolution, medicine, and public health · 2026Article
- Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review.Drugs · 2026Review
- Obesity in Cardiorenal syndrome: Management Opportunities and Challenges.Current hypertension reports · 2025Review
- Preserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy.Current cardiology reports · 2025Review
- The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review.Current cardiology reports · 2025Review
- Obesity paradox in coronary heart disease.Future cardiology · 2025Article
- Advancing Obstructive Sleep Apnea Management: Recent Trends from Conventional to Innovative Therapies.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
40721501What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.